Connable Office Inc. continued to hold its position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,303 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Connable Office Inc.’s holdings in Valeant Pharmaceuticals International were worth $1,164,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Canada Pension Plan Investment Board increased its position in shares of Valeant Pharmaceuticals International by 24,953.6% in the second quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock valued at $36,525,000 after buying an additional 2,096,100 shares during the period. Greatmark Investment Partners Inc. increased its position in shares of Valeant Pharmaceuticals International by 54.1% in the second quarter. Greatmark Investment Partners Inc. now owns 26,200 shares of the specialty pharmaceutical company’s stock valued at $453,000 after buying an additional 9,200 shares during the period. Seven Bridges Advisors LLC increased its position in shares of Valeant Pharmaceuticals International by 21.3% in the second quarter. Seven Bridges Advisors LLC now owns 18,237 shares of the specialty pharmaceutical company’s stock valued at $316,000 after buying an additional 3,206 shares during the period. IFP Advisors Inc increased its position in shares of Valeant Pharmaceuticals International by 0.4% in the second quarter. IFP Advisors Inc now owns 128,305 shares of the specialty pharmaceutical company’s stock valued at $2,220,000 after buying an additional 509 shares during the period. Finally, IPG Investment Advisors LLC bought a new position in shares of Valeant Pharmaceuticals International during the second quarter valued at about $203,000. Institutional investors and hedge funds own 51.14% of the company’s stock.

Shares of Valeant Pharmaceuticals International, Inc. (NYSE VRX) opened at 14.07 on Thursday. The stock has a 50 day moving average price of $16.61 and a 200-day moving average price of $13.38. Valeant Pharmaceuticals International, Inc. has a 52 week low of $8.31 and a 52 week high of $32.74. The company’s market capitalization is $4.90 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 60.62% and a negative net margin of 12.40%. The firm’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.88) earnings per share. Equities research analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Valeant Pharmaceuticals International, Inc. (VRX) Stake Held by Connable Office Inc.” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-vrx-stake-held-by-connable-office-inc/1469863.html.

Several research analysts recently issued reports on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $35.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday. Wells Fargo & Company reiterated an “underperform” rating and set a $9.00 price target on shares of Valeant Pharmaceuticals International in a research report on Thursday. Canaccord Genuity set a $14.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Thursday. Mizuho reiterated an “underperform” rating and set a $8.00 price target on shares of Valeant Pharmaceuticals International in a research report on Wednesday. Finally, Scotiabank upped their price target on shares of Valeant Pharmaceuticals International from $14.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $17.26.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.